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Background: The association between epidermal growth factor (EGF) gene +61A/G polymorphism (rs4444903) and
hepatocellular carcinoma (HCC) susceptibility has been widely reported, but the results were inconsistent. To clarify
the effect of this polymorphism on HCC risk, a meta-analysis was performed.
Methods: The PubMed, Embase, Cochrane Library, Web of Science, Chinese BioMedical Literature (CBM), Wanfang
and Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to identify relevant
studies published up to December 2013. Data were extracted independently by two authors. Odds ratios (ORs) and
95% confidence intervals (95% CIs) were calculated to assess the strength of association.
Results: A total of 16 studies including 2475 HCC cases and 5381 controls were included in this meta-analysis.
Overall, a significantly increased HCC risk was observed under all genetic models (G vs. A: OR = 1.383, P < 0.001, 95%
CI: 1.174-1.629; GG vs. GA + AA: OR = 1.484, P < 0.001, 95% CI: 1.198-1.838; GG + GA vs. AA: OR = 1.530, P < 0.001, 95%
CI: 1.217-1.924; GG vs. AA: OR = 1.958, P < 0.001, 95% CI: 1.433-2.675; GA vs. AA: OR = 1.215, P = 0.013, 95% CI: 1.041-
1.418). In the subgroup analyses by ethnicity, a significant association with HCC risk was found in Asian populations
(G vs. A: OR = 1.151, P = 0.001, 95% CI: 1.056-1.255), European populations (G vs. A: OR = 1.594, P = 0.027, 95% CI:
1.053-2.413, and African populations (G vs. A: OR = 3.599, P < 0.001, 95% CI: 2.550-5.080), respectively.
Conclusions: Our study shows that EGF +61A/G polymorphism is significantly associated with the increased
HCC risk, especially in Asian populations. Further large-scale and well-designed studies are required to confirm
this conclusion.
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Hepatocellular carcinoma (HCC) is the fifth most
common cancer and the third leading cause of cancer-
related death worldwide [1]. The estimated annual
number of cases exceeds 500 000, with a mean annual
incidence of around 3-4% [2]. Most cases of HCC* Correspondence: shusenzheng@zju.edu.cn
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unless otherwise stated.(about 80%) occur in eastern Asia and sub-Saharan
Africa, and China alone accounts for more than 50%
of the total cases [3]. Despite advances in the diagnosis
and treatment of HCC, it still has poor prognosis with
a five-year survival rate of 5% in developing countries
[4]. Carcinogenesis of HCC is a complex, multistep
and multifactorial process. Major risk factors for de-
velopment of HCC are chronic infection with hepatitis
B virus (HBV) or hepatitis C virus (HCV), liver cirrho-
sis, habitual alcohol abuse, high cigarette smoking,
and exposure to aflatoxin B1 [3,5]. However, not all in-
dividuals with exposure to the risk factors develophis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tors, might play important roles in the pathogenesis of
HCC.
Epidermal growth factor (EGF) was first isolated in
1962 [6]. It stimulates proliferation, differentiation
and tumorigenesis of epidermal and epithelial tissues
by binding to its receptor (EGFR) and, hence, activat-
ing several signal pathways [7,8]. EGF is a mitogen for
adult and fetal hepatocytes grown in culture, and its
expression is up-regulated during liver regeneration
[9]. Mounting evidence supports a role for EGF in ma-
lignant transformation, tumor growth and progression
[10]. The EGF gene is located on chromosome 4q25-
27 and contains 24 exons and 23 introns. The EGF
+61A/G polymorphism (rs4444903) is a common sin-
gle nucleotide polymorphism (SNP) in the 5′-untrans-
lated region (5′-UTR) of the EGF gene, modulating
the transcription of EGF gene and hence affecting
serum levels of EGF [11]. For now, there are a number
of studies conducted to examine the association between
EGF +61A/G polymorphism and HCC susceptibility, but
the results remain controversial and inconclusive [12-16].
These disparate findings may be due partly to insufficient
power, false-positive results and ethnic diversity.
Meta-analysis offers a powerful means of overcoming
the problems associated with small sample sizes, and
particularly, of overcoming the inadequate statistical
powers of genetic studies on complex traits [17]. There-
fore, in this study, we performed a meta-analysis from
all eligible studies to clarify the relationship between
EGF +61A/G polymorphism and HCC risk.
Methods
This meta-analysis followed the Preferred Reporting Items
for Systematic Reviews and Meta-analyses (PRISMA)
criteria [18].
Literature searching strategy
We conducted a computerized literature search of
PubMed, Embase, Cochrane Library, Web of Science,
Chinese BioMedical Literature (CBM), Wanfang and
Chinese National Knowledge Infrastructure (CNKI)
databases to identify all potential studies published up
to December 31, 2013. The following keywords and
subject terms were included in searching: “EFG” or
“Epidermal growth factor”, “liver cancer” or “hepato-
cellular carcinoma” or “HCC”, and “polymorphism” or
“variant” or “allele”. References of retrieved articles
and review articles were also screened.
Inclusion criteria
Studies included in the meta-analysis had to meet all the
following criteria: (1) evaluating the association between
EGF +61A/G polymorphism and HCC risk, (2) usingunrelated individuals, (3) providing sufficient data for es-
timating an odds ratio (OR) with its 95% confidence
interval (CI), (4) using case–control, cohort or cross-
sectional design, (5) published in English or Chinese.
The corresponding authors were contacted to obtain
missing information, and some studies were excluded if
critical missing information was not obtained. Reviews,
case reports, family-based studies, case-only studies, and
studies without sufficient data were all excluded. When
a study reported results on different subpopulations
based on ethnicity or geographical region, we treated
each subpopulation as a separate comparison. If more
than one article was published using the same subjects,
only the study with the largest sample size was selected.
Data extraction
All data were extracted independently by two investiga-
tors (Lifang Shao and Xiaobo Yu). Disagreement was re-
solved by discussion. The following data were extracted:
authors, name of journal, year of publication, ethnicity
and country of study population, inclusion and exclusion
criteria, characteristics of cases and controls, numbers of
HCC cases and controls, matching criteria, source of
controls, HCC confirmation, study design, genotyping
methods, genotype frequencies of cases and controls,
and interactions between environment factors or genes.
Quality score assessment
Quality of studies was independently assessed by the
same two investigators (Lifang Shao and Xiaobo Yu) ac-
cording to a set of predetermined criteria (Additional file
1: Table S1), which was extracted and modified from
previous studies [19,20]. These scores were based on
traditional epidemiological considerations, as well as
cancer genetic issues. Any disagreement was resolved by
discussion between the two investigators. The total
scores ranged from 0 (worst) to 24 (best). Studies scor-
ing <16 were classified as “low quality”, and those scor-
ing ≥16 as “high quality”.
Statistical analysis
The unadjusted OR with 95% CI was used to assess
the strength of the association between EGF +61A/G
polymorphism and HCC risk. The pooled ORs were
performed under the allelic contrast (G versus A), co-
dominant model (homozygote comparison: GG versus
AA, heterozygote comparison: GA versus AA), dominant
model (GG +GA versus AA), and recessive model (GG
versus GA +AA), respectively. Between-study heterogen-
eity was measured using a Q-statistic test [21] and an
I-square statistic [22]. P less than 0.10 (P < 0.10) was
considered representative of significant statistical hetero-
geneity because of the low power of the statistic. I2 ranges
between 0 and 100%, and represents the proportion of
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geneity rather than chance. I2 values of 25%, 50%, and 75%
were defined as low, moderate, and high estimates. If
the significant Q-statistic indicated heterogeneity
across studies, the random-effects model (DerSimo-
nian and Laird method) was used, otherwise the fixed-
effects model (Mantel-Haenszel method) was adopted
[23]. The Z test was used to assess the significance of
the pooled OR and a P-value less than 0.05 (P < 0.05)
was considered significant.
Subgroup analyses were stratified by racial descent,
study quality, source of controls, type of controls, and
number of cases, respectively. Furthermore, meta-
regression analysis [24] was performed to investigate
five potential sources of heterogeneity including ethni-
city (Asian populations versus not Asian populations),
study quality (high quality studies versus low quality
studies), source of controls (Hospital-based versus
Population-based), type of controls (healthy controls
versus controls with chronic liver diseases) and num-
ber of cases (<100 versus ≥100). Statistical significance
was defined as a P-value less than 0.10 (P < 0.10) be-
cause of the relatively weak statistical power.database searching (n=412):
   PubMed (n=86)
   Embase (n=81)
   Cochrane (19)
   Web of science (110)
   CBM (n=17)
   CNKI (n=67)
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Figure 1 Flow diagram of the study selection process.To evaluate the stability of the results, sensitivity ana-
lyses were performed by sequential omission of individ-
ual studies under various comparisons in overall and
Asian populations, respectively. Publication bias was in-
vestigated by funnel plot. Funnel plot asymmetry was
assessed by the method of Egger’s linear regression test
[25]. Hardy-Weinberg equilibrium (HWE) was tested by
the χ2 test. All P-values were two-sided. Data analyses
were performed using the software Stata version 11.0
(StataCorp LP, College Station, TX, USA).
Results
Eligible studies
The present study met the PRISMA statement (Additional
file 2: Checklist S1). A total of 413 potentially relevant re-
cords were initially obtained through searching the data-
bases. After removing 127 duplications, 241 records were
excluded because of obvious irrelevance to our study aim
by browsing the titles and abstracts. According to the in-
clusion criteria, 32 of the remaining 45 records were fur-
ther excluded by review of the full texts. The flow chart of
the selection process was shown in Figure 1. In total, 13
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tion as a separate study. As a result, 16 studies (13 articles)
including 2475 HCC cases and 5381 controls were identi-
fied and included in this meta-analysis [12-16,26-33].
Characteristics of studies and subjects
The main characteristics of the 16 included studies were
listed in Table 1. All articles were published in English
except for one [26]. Of all the eligible studies, 9 were
conducted in Asian populations, 2 in European popula-
tions, 2 in African populations, and 3 in mixed popula-
tions with more than 72% Caucasians. In all the studies,
the cases were histologically confirmed (11 studies) or diag-










































































































































HB, Hospital-based; PB, Population-based; HBV, control subjects were hepatitis B vir
polymerase chain reaction-restriction fragment length polymorphism; HWE: Hardy-Wchanges (abdominal ultrasound and Triphasic computed
tomography). All the controls were free of cancer. Two
studies used healthy populations, 4 studies used patients
with chronic liver diseases (HBV infection, HCV infection,
cirrhosis), and 10 studies included both healthy subjects
and patients with chronic liver diseases as controls. Seven
studies matched in age, 10 studies matched in gender, and
9 studies matched in hepatitis virus infection status. The
sample size of the total participants ranged from 80 to
1774, with a mean of 491. The quality scores for the indi-
vidual studies ranged from 11.5 to 21, with 9 out of the 16
studies classified as high quality. Fifteen studies used per-
ipheral blood, and one study used either blood or liver tis-
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us carriers; HCV, control subjects were hepatitis C virus carriers; PCR-RFLP,
einberg equilibrium in control population; Y, yes; N, no.
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morphism assay (PCR-RFLP), and three studies used Taq-
man method to genotype the EGF +61 A/G polymorphism.
While genotyping, 10 studies repeated a portion of samples,
and only 4 studies described use of blindness of the status
of DNA samples. The genotype distribution in the controls
of all studies was consistent with HWE.
Meta-analysis results
The frequency of +61G allele was 65% in Asian controls,
42% in European controls, and 30% in African controls.
There were significant differences in terms of +61G al-
lele frequency among the three major ethnicities (P <
0.001). Table 2 indicated the associations between EGF
+61A/G polymorphism and HCC risk. Overall, the re-
sults of pooling all studies showed that the EGF +61A/G
polymorphism was significantly associated with an
increased HCC risk under all genetic models (G vs. A:
OR = 1.383, P < 0.001, 95% CI: 1.174-1.629, I2 = 75.4%,
Pheterogeneity < 0.001, Figure 2; GG vs. GA + AA: OR =
1.484, P < 0.001, 95% CI: 1.198-1.838, I2 = 69.3%, Phetero-
geneity < 0.001; GG + GA vs. AA: OR = 1.530, P < 0.001,
95% CI: 1.217-1.924, I2 = 53.5%, Pheterogeneity = 0.006; GG
vs. AA: OR = 1.958, P < 0.001, 95% CI: 1.433-2.675, I2 =
65.2%, Pheterogeneity < 0.001; GA vs. AA: OR = 1.215, P =
0.013, 95% CI: 1.041-1.418, I2 = 19.7%, Pheterogeneity = 0.229)
(Table 2).
In the subgroup analyses based upon ethnicity, a sig-
nificantly elevated association between EGF +61A/G
polymorphism and HCC risk was observed in Asian
populations (G vs. A: OR = 1.151, P = 0.001, 95% CI:
1.056-1.255, I2 = 4.6%, Pheterogeneity = 0.397), European
populations (G vs. A: OR = 1.594, P = 0.027, 95% CI:
1.053-2.413, I2 = 0.0%, Pheterogeneity = 0.582), and African
populations (G vs. A: OR = 3.599, P < 0.001, 95% CI:
2.550-5.080, I2 = 57.6%, Pheterogeneity = 0.125), respectively
(Figure 2). When stratifying by study quality, the results
showed that EGF +61A/G polymorphism was associated
with an increased HCC risk both in high-quality studies
(G vs. A: OR = 1.178, P < 0.001, 95% CI: 1.077-1.289, I2
= 0.0%, Pheterogeneity = 0.539) and in low-quality studies
(G vs. A: OR = 1.740, P = 0.010, 95% CI: 1.144-2.648, I2
= 87.1%, Pheterogeneity < 0.001). In the subgroup analyses
by source of controls, the results showed that EGF
+61A/G polymorphism was significantly associated with
HCC risk in hospital-based studies (G vs. A: OR = 1.439,
P < 0.001, 95% CI: 1.205-1.719, I2 = 75.8%, Pheterogeneity <
0.001), but not in population-based studies (G vs. A: OR
= 1.087, P = 0.202, 95% CI: 0.956-1.236, I2 = 0.0%, Phetero-
geneity = 0.815). Furthermore, according to chronic liver
disease status in Asian controls, a significant association
between EGF +61A/G polymorphism and HCC risk was
obtained in patients with chronic liver diseases (G vs. A:
OR = 1.165, P = 0.017, 95% CI: 1.028-1.321, I2 = 23.3%,Pheterogeneity = 0.266), and in healthy controls (G vs. A:
OR = 1.142, P = 0.043, 95% CI: 1.004-1.299, I2 = 4.2%,
Pheterogeneity = 0.383) (Table 2).
Heterogeneity analysis
Q-statistic indicated statistically significant heterogeneity
among all studies under all genetic models except for
heterozygote comparison (Table 2). However, in the
subgroup analyses by ethnicity, the between-study het-
erogeneity was not observed in Asian populations,
European populations or African populations. More-
over, meta-regression indicated that both ethnicity and
study quality significantly contributed to the hetero-
geneity for EGF +61A/G polymorphism (Table 3).
Sensitivity analysis and publication bias
Sensitivity analysis was performed by sequential omis-
sion of individual studies. The pooled ORs were con-
sistently significant in overall populations or Asian
populations by omitting one study at a time under the
allelic contrast, recessive model and homozygote com-
parison, suggesting robustness of our results. Funnel
plots and Egger’s test were performed to assess publi-
cation bias. The results showed that bias may exist in
overall populations (G vs. A: t = 2.62, P = 0.020; GG vs.
GA + AA: t = 2.70, P = 0.017), but not in Asian popula-
tions (G vs. A: t = 1.71, P = 0.130; GG vs. GA + AA: t =
1.25, P = 0.250) (Figure 3).
Discussion
This article investigated the relationship between EGF
+61A/G polymorphism and HCC susceptibility. A total
of 16 studies from 13 articles (2475 cases and 5381 con-
trols) were finally included in this meta-analysis. Overall,
the EGF +61A/G polymorphism was significantly associ-
ated with an increased HCC risk under all genetic
models. However, considerable heterogeneity was de-
tected across studies. Meta-regression showed that
both ethnicity and study quality significantly contrib-
uted to the heterogeneity for EGF +61A/G poly-
morphism. Nevertheless, in the subgroup analyses by
ethnicity and study quality, this significant association
still existed in each subgroup, and the between-study
heterogeneity became insignificant in Asian, European
or African populations. Moreover, sensitivity analysis
further strengthened the validity of the positive associ-
ation in overall populations, and in Asian populations,
indicating robustness of our results.
It is possible that the effects of genetic factors related
to cancer are different across various ethnic popula-
tions. In this study, ethnicity was identified as a potential
source of between-study heterogeneity by meta-regression
and subgroup analyses. Although the reason for these dis-
crepancies was not well known, some possibilities should





GG vs. GA + AA GG + GA vs. AA GG vs. AA GA vs. AA \G vs. A
OR (95% CI) I2(%) OR (95% CI) I2(%) OR (95% CI) I2(%) OR (95% CI) I2(%) OR (95% CI) I2(%)
Overall 16 2475/5381 1.48 (1.20-1.84)* 69.3** 1.53 (1.22-1.92)* 53.5** 1.96 (1.43-2.68)* 65.2** 1.22 (1.04-1.42)* 19.7 1.38 (1.17-1.63)* 75.4**
Racial descent
Asian 9 2018/3655 1.19 (1.06-1.34)* 24.9 1.20 (1.01-1.43)* 16.3 1.40 (1.14-1.71)* 1.3 1.10 (0.92-1.33) 23.5 1.15 (1.05-1.26)* 4.6
European 2 62/438 2.10 (1.07-4.13)* 12.6 1.62 (0.84-3.13) 0.0 2.51 (1.11-5.71)* 0.0 1.30 (0.64-2.63) 0.0 1.59 (1.05-2.41)* 0.0
African 2 153/165 6.33 (3.39-11.83)* 46.8 3.69 (2.23-6.10)* 0.0 9.34 (4.61-18.91)* 19.4 2.11 (1.21-3.67)* 0.0 3.60 (2.55-5.08)* 57.6
Mixed 3 242/1123 1.55 (0.79-3.06) 77.3** 1.52 (1.08-2.16)* 46.9 1.94 (0.87-4.33) 73.1** 1.37 (0.94-2.00) 11.0 1.45 (0.93-2.26) 77.1**
Study quality
High quality 9 1688/4339 1.22 (1.08-1.38)* 21.0 1.26 (1.04-1.52)* 0.0 1.36 (1.11-1.67)* 0.0 1.16 (0.94-1.42) 0.0 1.18 (1.08-1.29)* 0.0
Asian 6 1487/3003 1.22 (1.07-1.38)* 0.0 1.23 (0.99-1.54) 8.5 1.34 (1.06-1.69)* 0.0 1.13 (0.89-1.43) 23.2 1.17 (1.06-1.29)* 0.0
Others 3 201/1336 1.29 (0.65-2.58) 69.0** 1.32 (0.92-1.91) 0.0 1.45 (0.94-2.23) 37.6 1.25 (0.84-1.85) 0.0 1.22 (0.98-1.52) 50.0
Low quality 7 787/1042 2.28 (1.23-4.23)* 82.7** 1.90 (1.17-3.09)* 74.3** 3.06 (1.62-5.76)* 72.9** 1.45 (1.02-2.07)* 44.1** 1.74 (1.14-2.65)* 87.1**
Asian 3 531/652 1.31 (0.72-2.38) 69.6** 1.14 (0.86-1.51) 49.3 1.59 (1.05-2.43)* 32.8 1.07 (0.80-1.44) 48.8 1.14 (0.85-1.53) 60.5**
Others 4 256/390 3.57 (1.94-6.60)* 53.4** 2.89 (1.98-4.20)* 22.6 5.67 (3.52-9.14)* 41.6 1.88 (1.25-2.82)* 0.0 2.47 (1.61-3.80)* 65.8**
Source of controls
Population-based 5 940/1451 1.04 (0.88-1.24) 0.0 1.28 (0.99-1.67) 0.0 1.26 (0.94-1.67) 0.0 1.29 (0.98-1.71) 0.0 1.09 (0.96-1.24) 0.0
Asian 3 805/1017 1.07 (0.89-1.29) 0.0 1.29 (0.94-1.77) 9.1 1.32 (0.95-1.84) 0.0 1.26 (0.90-1.76) 40.1 1.10 (0.95-1.27) 0.0
Others 2 135/434 0.87 (0.54-1.40) 0.0 1.27 (0.79-2.02) 0.0 1.07 (0.60-1.90) 0.0 1.37 (0.83-2.25) 0.0 1.04 (0.78-1.39) 0.0
Hospital-based 15 2358/3930 1.59 (1.27-1.99)* 67.3** 1.57 (1.21-2.04)* 58.5** 2.10 (1.49-2.96)* 66.6** 1.18 (1.00-1.39) 27.6 1.44 (1.21-1.72)* 75.8**
Asian 9 2018/2638 1.23 (1.09-1.39)* 20.2 1.16 (0.97-1.40) 26.7 1.38 (1.11-1.71)* 22.6 1.06 (0.88-1.28) 24.6 1.16 (1.06-1.27)* 17.6
Others 6 340/1292 2.79 (1.72-4.53)* 54.0** 2.31 (1.70-3.14)* 37.9 3.77 (2.07-6.88)* 55.5** 1.61 (1.16-2.25)* 0.0 2.08 (1.44-2.98)* 69.0**
Type of controls
Healthy controls 8 1153/1708 1.10 (0.94-1.29) 34.3 1.40 (1.11-1.76)* 7.8 1.44 (1.11-1.86)* 31.7 1.35 (1.05-1.72)* 0.0 1.18 (1.00-1.41) 43.4**
Asian 5 998/1254 1.11 (0.94-1.32) 36.8 1.36 (1.04-1.79)* 0.0 1.47 (1.09-1.97)* 8.5 1.28 (0.96-1.71) 0.0 1.14 (1.00-1.30)* 4.2
Others 3 155/454 1.01 (0.65-1.57) 51.2 1.95 (0.81-4.73) 58.4** 2.08 (0.59-7.31) 65.1** 1.54 (0.96-2.47) 16.6 1.59 (0.77-3.29) 75.5**
Patients with chronic liver diseases 12 1395/2696 1.74 (1.29-2.36)* 70.0** 1.87 (1.30-2.67)* 58.7** 2.58 (1.60-4.16)* 69.9** 1.36 (1.09-1.70)* 36.0 1.56 (1.23-1.99)* 76.9**
Asian 5 1055/1424 1.19 (1.01-1.40)* 11.0 1.64 (0.95-2.84) 61.7** 1.77 (1.02-3.06)* 59.1** 1.53 (0.86-2.72) 62.6** 1.17 (1.03-1.32)* 23.3
Others 7 340/1272 2.73 (1.74-4.28)* 45.2** 2.22 (1.64-3.01)* 34.2 3.53 (2.01-6.20)* 47.5** 1.55 (1.12-2.16)* 0.0 1.98 (1.41-2.79)* 64.4**
Number of cases
≥100 10 2195/3868 1.27 (1.01-1.60)* 72.6** 1.44 (1.07-1.94)* 66.1** 1.66 (1.13-2.43)* 71.8** 1.24 (0.98-1.58) 39.7** 1.26 (1.03-1.53)* 80.7**
Asian 8 1945/3538 1.17 (1.04-1.32)* 0.0 1.16 (0.97-1.40) 16.6 1.34 (1.08-1.65)* 0.0 1.09 (0.90-1.32) 31.3 1.13 (1.04-1.24)* 0.0











Table 2 Main results of meta-analysis for EGF +61A/G polymorphism and HCC risk (Continued)
<100 6 280/1513 2.28 (1.68-3.10)* 0.0 1.79 (1.31-2.45)* 0.0 2.82 (1.93-4.13)* 0.0 1.40 (1.00-1.96) 0.0 1.74 (1.43-2.12)* 0.0
Asian 1 73/117 2.62 (1.20-5.74)* - 1.63 (0.89-3.00) - 3.00 (1.27-7.10)* - 1.29 (0.67-2.49) - 1.70 (1.11-2.59)* -
Others 5 207/1396 2.22 (1.59-3.10)* 0.0 1.85 (1.28-2.66)* 0.0 2.78 (1.82-4.25)* 0.0 1.44 (0.97-2.14) 0.0 1.75 (1.41-2.18)* 0.0
OR, odds ratio; 95% CI, 95% confidence interval.
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Figure 2 Forest plot for the association between EGF +61A/G polymorphism and HCC risk stratified according to different ethnicities (G vs. A).
For each study, the estimate of OR and its 95% CI is plotted with a diamond (◆) and a horizontal line. The size of a box (gray square) is
proportional to the weight that the study has in calculating the summary effect estimate (`). The center of the diamond indicates the OR
and the ends of the diamond correspond to the 95% CI.
Jiang et al. BMC Cancer  (2015) 15:314 Page 8 of 12be considered. First, there were significant differences in
terms of +61G allele frequency among the three major eth-
nicities. The frequency of EGF +61G allele was greatest inAsian populations (65%), intermediate in European popula-
tions (42%), and lowest in African populations (30%). The
higher HCC prevalence among Asian populations may be
Table 3 Main results of meta-regression for EGF +61A/G polymorphism and HCC risk
Factor GG vs. GA + AA GG + GA vs. AA GG vs. AA GA vs. AA G vs. A
t P t P t P t P t P
Ethnicity 2.18 0.047 1.93 0.075 2.05 0.060 1.54 0.146 2.57 0.022
Study quality 2.06 0.059 1.35 0.199 2.36 0.034 0.79 0.443 1.83 0.088
Jiang et al. BMC Cancer  (2015) 15:314 Page 9 of 12partly ascribed to the higher prevalence of EGF +61G allele.
The frequency of EGF +61G among the controls of all
studies was consistent with that in 1000 Genome Project,
except for two studies [13,28]. The omission of these two
studies did not substantially alter the results, indicating reli-
ability of our results. Second, different linkage disequilib-
rium patterns may contribute to the discrepancy. The EGF




















Figure 3 Begg’s funnel plot of the Egger’s test for publication bias of EGF
B: Asian populations. The horizontal line in the funnel plot indicates summ
confidence intervals for a given standard error.causal variant in one ethnic population, but not in another.
Third, clinical heterogeneity such as age, gender ratio, life
style and disease severity may also explain the discrepancy.
The discrepancy might be due to genetic background and
environmental exposure differences. Last but not least,
owing to the limited number of studies in European and
African populations included in this meta-analysis, the




+61A/G polymorphism and HCC risk (G vs. A). A: Overall populations;
ary estimate, whereas the sloping lines indicate the expected 95%
Jiang et al. BMC Cancer  (2015) 15:314 Page 10 of 12Therefore, further studies were needed to investigate the
reason for this discrepancy.
Study design is an area of concern and can influence
the interpretation of the results of meta-analysis. Among
the eligible studies, there were 15 hospital-based studies,
but only 5 population-based studies. Our results showed
that EGF +61A/G polymorphism was significantly asso-
ciated with HCC risk in hospital-based studies, but
not in population-based studies. Therefore, the results
should be treated with caution, because controls from
hospital-based studies may not represent the general
population. Larger population-based studies were re-
quired to further confirm the association between EGF
+61A/G polymorphism and HCC susceptibility. Further-
more, according to chronic liver disease status in Asian
controls, a significant association between EGF +61A/G
polymorphism and HCC risk was obtained both in con-
trols with chronic liver diseases, and in healthy controls,
indicating reliability of the pooled results in Asian popu-
lations. Besides, all Asian studies were based on Chinese
populations except for one Japanese study [14]. The fre-
quency of EGF +61G allele was a little lower in Chinese
populations than that in Japanese populations, according
to 1000 Genome Project and our results. Geographical
discrepancy should be considered in the analyses. The
pooled results of these Chinese studies were consistent
with those from Asian studies. Therefore, EGF +61A/G
polymorphism may be associated with HCC risk in
Asian populations, especially in Chinese populations. In
addition, study quality was also identified as a potential
source of heterogeneity by meta-regression. In this
meta-analysis, 9 of the 16 studies were classified as high
quality. Studies with low-quality design usually did not
exclude those possible factors that may bias the estimate
of the real effects and may result in incorrect conclu-
sions. However, the association between EGF +61A/G
polymorphism and HCC risk was significant in both
high-quality and low-quality studies, suggesting that this
bias cannot affect the final results.
Epidermal growth factor is a mitogen for hepatocytes,
and plays a critical role in liver tissue regeneration, ma-
lignant transformation, tumor growth and progression
[34]. Transgenic mice with liver-targeted overexpression
of the secreted EGF fusion protein develop hepatocellu-
lar carcinoma, and blockade of EGF receptor activity
halt the development and progression of HCC [35-37].
Thus, overexpression of EGF might be an important step
toward development of liver cancer. For EGF +61A/G
polymorphism, several studies have demonstrated that
GG or GA genotype was associated with significantly
higher EGF production both in normal peripheral blood
mononuclear cell cultures and in serum and liver tissues
of individuals [11,12,29]. It was thought that EGF +61A/
G polymorphism might be correlated to HCC. Ourresults showed that EGF +61G allele was significantly
associated with an increased HCC risk, which was con-
sistent with the hypothesis. However, the molecular
mechanism of the association between EGF +61A/G
polymorphism and HCC risk remains relatively unclear.
To our knowledge, this present meta-analysis is the
most comprehensive one related to the relationship be-
tween EGF +61A/G polymorphism and HCC risk. Com-
pared with the previous meta-analysis [38], another
eight studies were included in this meta-analysis. The
sample size of total participants in our study (2475 cases
and 5381 controls) was much larger than that in the
previous one (1304 cases and 2613 controls). Thus, the
pooled results were more reliable and robust in our
study. Furthermore, the quality of the included studies
was evaluated in our study, but not in the previous one.
Meta-regression was performed to explore the sources
of heterogeneity among studies, which allowed a more
thorough examination and appropriate qualification of
our results.
Despite our efforts in performing a comprehensive
analysis, several limitations should be considered. Firstly,
obvious publication bias was detected in overall popula-
tions. Bias may result from our exclusion of unpublished
data, as well as studies published in languages other than
English and Chinese. Secondly, the controls were not
uniformly defined. Some studies were population-based,
while others were hospital-based. Considering the over-
whelming impact of chronic liver diseases on HCC de-
velopment, controls were divided into healthy controls
and controls with chronic liver diseases. The subgroup
analyses showed that the significant association between
EGF +61A/G and HCC was present both in healthy
controls and in patients with chronic liver diseases, indi-
cating the role of EGF +61A/G in the risk of HCC, re-
gardless of type of controls. Moreover, the pooled ORs
for individuals with chronic liver diseases were higher
than those for healthy controls under all genetic models.
Therefore, the chronic liver diseases may change the
environment in vivo and mediate the ability of genetic
factors to contribute to HCC. More studies should be
designed to investigate the role of EGF polymorphisms
in combination with chronic liver diseases in HCC
pathogenesis. Thirdly, our meta-analysis was based on
unadjusted estimates. If individual data were available,
adjusted estimates by confounding factors could be ob-
tained to conduct a more precise analysis. Fourthly,
gene-gene and gene-environment interactions were not
addressed in our meta-analysis due to lack of sufficient
data. Aside from genetic factors, other factors such as
exposure to aflatoxin B1, high cigarette smoking, and
habitual alcohol abuse might also play vital roles in the
development of HCC. However, we could not perform
subgroup analyses based on environmental exposure
Jiang et al. BMC Cancer  (2015) 15:314 Page 11 of 12owing to the limited reported information on such asso-
ciations in those included studies. Finally, the number of
studies included in the meta-analysis for European pop-
ulations and African populations was relatively small,
which may lead to low statistical power and generate
fluctuation in estimation.
Conclusions
In summary, this meta-analysis suggests that EGF gene
+61A/G polymorphism is significantly associated with
the increased risk of HCC, particularly in Asian popula-
tions. Further well-designed and large-scale studies with
the consideration of gene-gene and gene-environment
interactions should be conducted to investigate the asso-
ciation in different ethnic populations.
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